Journal of Hepatology最新文献

{"title":"Reply to: “Insights into Fracture Risk with Tenofovir and Entecavir: Evidence from Pharmacovigilance Data”","authors":"Jimmy Che-To Lai, Mary Yue Wang, Terry Cheuk-Fung Yip","doi":"10.1016/j.jhep.2024.11.019","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.019","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions:</h2>All authors were responsible for the study concept, data acquisition and analysis, the integrity of the data and the accuracy of the data analysis, the drafting, and the critical revision of the manuscript for important intellectual content, and approved the final version of the article. Terry Yip is the submission’s guarantor of the article.</section></section><section><section><h2>Financial support:</h2>None</section></section><section><section><h2>Declaration of Competing Interest:</h2>Jimmy Lai has served as a speaker for Gilead Sciences and an advisory board committee for Gilead Sciences and Boehringer Ingelheim.Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences.Mary Wang declares that she has no competing interests.We extend our sincere gratitude to Ge <em>et al.</em> [1] for their valuable insights on our territory-wide cohort study, which involved patients identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis","authors":"Jimmy Che-To Lai, Grace Lai-Hung Wong, Yee-Kit Tse, Vicki Wing-Ki Hui, Mandy Sze-Man Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip","doi":"10.1016/j.jhep.2024.11.018","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.018","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and treatment of patients at high risk of adverse outcomes. Clinical outcomes and the effect of antiviral therapy on the indeterminate phase remain unclear. We performed a systematic review and meta-analysis to study the incidence of adverse clinical outcomes including hepatocellular carcinoma (HCC), cirrhosis, and hepatic decompensation, and the effect of antiviral therapy, in the indeterminate phase.&lt;h3&gt;Methods&lt;/h3&gt;Two investigators independently searched Embase, MEDLINE, Web of Science and China National Knowledge Infrastructure from 1/1/2007 to 31/12/2023. Three investigators independently assessed study eligibility and quality. We included cohort studies and randomised controlled trials (RCTs) allowing calculation of the incidence rate of adverse clinical outcomes, and cross-sectional studies that reported the prevalence of moderate-to-severe inflammation and different degrees of fibrosis. Incidence rates and prevalence were pooled using generalised linear mixed-effects models and random-effects models, respectively.&lt;h3&gt;Results&lt;/h3&gt;One hundred and three studies (70 case-control studies [18,739 patients], 32 cohort studies [15,118 patients], 1 RCT [160 patients]) were included. The annual incidence rate of HCC in patients in the indeterminate phase was 0.32% (95% CI 0.21-0.48%, I&lt;sup&gt;2&lt;/sup&gt;=85.7%), and those of cirrhosis and hepatic decompensation were 0.67% (95% CI 0.30-1.49%, I&lt;sup&gt;2&lt;/sup&gt;=94.3%) and 0.34% (95% CI 0.17-0.69%, I&lt;sup&gt;2&lt;/sup&gt;=51.8%), respectively. The pooled prevalence of moderate-to-severe liver inflammation, significant fibrosis, advanced fibrosis, and cirrhosis was 40.7, 39.7%, 17.9%, and 7.2%, respectively. Use of antiviral therapy was associated with a lower risk of HCC in patients in the indeterminate phase (adjusted incidence rate ratio 0.38, 95% CI 0.18-0.79, p=0.009).&lt;h3&gt;Conclusions&lt;/h3&gt;Patients in the indeterminate phase are at risk of developing advanced liver disease and HCC. Although inherent heterogeneity across studies limited the evidence to support expanding treatment to all patients in the indeterminate phase, antiviral therapy may reduce the risk of HCC development in high-risk subgroups.&lt;h3&gt;IMPACT AND IMPLICATIONS&lt;/h3&gt;Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and not all of these patients are indicated for antiviral treatment. Based on the systematic review and meta-analysis with significant heterogeneity across studies, patients in the indeterminate phase are at risk of developing hepatocellular carcinoma (HCC), cirrhosis, and hepatic decompensation. Meta-regression findings on platelet count, positive HBeAg, and age highlighted the importance of liver fibrosis assessment, accurate phase classification, and timely detection of pha","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"46 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective","authors":"Yoon E. Shin, Jae Young Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim","doi":"10.1016/j.jhep.2024.11.022","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Data availability statement (delete if not applicable)</h2>Raw data were generated at Korean Health Insurance Review and Assessment Service (HIRA) database. Derived data supporting the findings of this study are available from the corresponding author Jeong Ju Yoo on request.</section></section><section><section><h2>Authors' contributions</h2>Conceptualization, Jeong-Ju Yoo; Methodology, Jae Young Kim; Formal analysis, Jae Young Kim; Investigation, Sang Gyune Kim and Young Seok Kim; Resources, Sang Gyune Kim and Young Seok Kim; Writing - Original Draft, Yoon E Shin and Jeong-Ju Yoo; Writing - Review &amp; Editing, all authors</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>NonePlease refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>This study was supported by the Soonchunhyang University Research Fund.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"254 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical data-driven modelling on the initiation time of antiviral prophylaxis among pregnant women with chronic hepatitis B infection","authors":"Mingwang Shen, Shihao He, Naijuan Yao, Rui Li, Jing Wang, Wenting Zhong, Jinyan Wang, Huihui Wang, Li Xie, Guihua Zhuang, Lei Zhang, Tianyan Chen","doi":"10.1016/j.jhep.2024.11.017","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.017","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;The risk of mother-to-child transmission (MTCT) for pregnant women with chronic hepatitis B (CHB) infection still exists, especially for those with high HBV DNA level. The guidelines for initiating prophylaxis for pregnant women with CHB vary across countries. We aimed to explore the latest prophylaxis initiation time for these women.&lt;h3&gt;Methods&lt;/h3&gt;We collected the real-world clinical data of 328 pregnant women with CHB infection aged 20-49 treated by telbivudine (LdT) or tenofovir disoproxil fumarate (TDF) from July 2010 to December 2020 in China. A mathematical model was developed to describe the viral kinetics of HBV after prophylaxis. We calculated the time required to reduce viral load below the threshold value of 5.3 log&lt;sub&gt;10&lt;/sub&gt; IU/mL. We derived the prophylaxis initiation time by subtracting the required time to threshold from the childbirth gestational week.&lt;h3&gt;Results&lt;/h3&gt;The median time for 328 women to reduce HBV DNA levels below the threshold of 5.3 log&lt;sub&gt;10&lt;/sub&gt; IU/mL was 4.2 (range: 0.2-12.8) weeks, corresponding to prophylaxis initiation time of no later than 35.1 (25.2-41.4) weeks. Specifically, for women with viral loads &gt; 8.0 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, prophylaxis should be initiated before 33.9 (25.2-39.5) weeks, and particularly before the lower bound of 25.2 weeks, to maximize clinical safety. For women with viral load &gt;7.0 to &lt;span&gt;&lt;span style=\"display: none;\"&gt;&lt;/span&gt;&lt;span data-mathml='&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;&amp;#x2264;&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;' role=\"presentation\" style=\"position: relative;\" tabindex=\"0\"&gt;&lt;span aria-hidden=\"true\"&gt;[Math Processing Error]&lt;/span&gt;&lt;span role=\"presentation\"&gt;&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo is=\"true\" linebreak=\"goodbreak\" linebreakstyle=\"after\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt;&lt;/span&gt;&lt;script type=\"math/mml\"&gt;&lt;math&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/script&gt;&lt;/span&gt; 8.0 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, prophylaxis should be initiated before 35.5 (28.6-39.8) weeks, and for women with viral load &gt;5.3 to &lt;span&gt;&lt;span style=\"display: none;\"&gt;&lt;/span&gt;&lt;span data-mathml='&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;&amp;#x2264;&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;' role=\"presentation\" style=\"position: relative;\" tabindex=\"0\"&gt;&lt;span aria-hidden=\"true\"&gt;[Math Processing Error]&lt;/span&gt;&lt;span role=\"presentation\"&gt;&lt;math xmlns=\"http://www.w3.org/1998/Math/MathML\"&gt;&lt;mrow is=\"true\"&gt;&lt;mo is=\"true\" linebreak=\"goodbreak\" linebreakstyle=\"after\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/span&gt;&lt;/span&gt;&lt;script type=\"math/mml\"&gt;&lt;math&gt;&lt;mrow is=\"true\"&gt;&lt;mo linebreak=\"goodbreak\" linebreakstyle=\"after\" is=\"true\"&gt;≤&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/script&gt;&lt;/span&gt; 7.0 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, prophylaxis should be initiated befo","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"16 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastering the Narrative: Precision Reporting of Risk and Outcomes in Liver Transplantation","authors":"Femke H.C. de Goeij, Chase J. Wehrle, Fariba Abassi, Sangeeta Satish, Mingyi Zhang, Rebecca Panconesi, Koji Hashimoto, Charles M. Miller, Wojciech G. Polak, Pierre-Alain Clavien, Jeroen de Jonge, Andrea Schlegel","doi":"10.1016/j.jhep.2024.11.013","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.013","url":null,"abstract":"Liver transplantation is associated with a high risk of postoperative complications due to the complexity of the surgical procedure, recipient disease severity and wide range of graft quality which remains somewhat unpredictable. However, survival rates after transplantation continue to improve and the focus has thus turned to other clinically relevant endpoints including posttransplant complications, patient quality of life and costs. Procedures like liver transplantation offer the entire spectrum of postsurgical events, even in donor-recipient constellations deemed of low risk within recently defined benchmark criteria. The Clavien-Dindo classification and the Comprehensive Complication Index (CCI®) were established to assess postoperative morbidity and are widely utilized across surgical specialties. However, these scores unfortunately are associted with observer variability when used in practice, mainly due to the lack of uniform definitions. Interventions required to treat a specific complication are the main drivers of clinically relevant complications, which may result in under- or over-scoring of posttransplant events.The number and grade of complications is frequently used as a metric assessing specific donor-recipient-risk-profiles and in assessing new approaches such as machine perfusion. Thus, accurate stratification is critical to comparing various potential risk factors. The concept of Benchmarking was recently introduced in surgery and transplantation as a mechanism of standardizing expected donor/recipient risk with outcomes within the first year after surgery. The management of complications, however, differs significantly worldwide, as does the rating scale assigned to various complications. This may lead to inhomogeneous interpretation of study results, leading to difficulty in assessing the clinical effects of novel preservation technologies and other therapeutics in liver transplantation. It also limits generalizability of study findings between countries, centers, and even providers.This article critically discusses frequent challenges associated with risk and outcome assessment following major surgery with a particular focus in liver transplantation.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"12 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142642706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing strengths and limitations of ctDNA in advanced biliary tract cancer genomic profiling.","authors":"Peng Luo, Anqi Lin, Kai Miao","doi":"10.1016/j.jhep.2024.11.015","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.015","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":26.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"My last Editorial as Editor-in-Chief of the Journal of Hepatology","authors":"Paolo Angeli","doi":"10.1016/j.jhep.2024.09.021","DOIUrl":"10.1016/j.jhep.2024.09.021","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"81 6","pages":"Pages 918-920"},"PeriodicalIF":26.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance” [J Hepatol 74 (5) 2021 1038–1052]","authors":"Tongxin Wang ,&nbsp;Kai Chen ,&nbsp;Weilei Yao ,&nbsp;Ruilong Zheng ,&nbsp;Qiongyu He ,&nbsp;Jun Xia ,&nbsp;Juan Li ,&nbsp;Yafei Shao ,&nbsp;Li Zhang ,&nbsp;Lu Huang ,&nbsp;Longshan Qin ,&nbsp;Mingming Xu ,&nbsp;Zheng Zhang ,&nbsp;Dingyu Pan ,&nbsp;Zhen Li ,&nbsp;Feiruo Huang","doi":"10.1016/j.jhep.2024.09.001","DOIUrl":"10.1016/j.jhep.2024.09.001","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"81 6","pages":"Page 1100"},"PeriodicalIF":26.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Concordance and Clinical Utility of ctDNA Profiling in Advanced Biliary Tract Cancer.","authors":"Kui Wang, Yuhua Chen, Yanqing Li","doi":"10.1016/j.jhep.2024.11.014","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.014","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":26.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JHEP at a Glance December 2024","authors":"","doi":"10.1016/S0168-8278(24)02588-1","DOIUrl":"10.1016/S0168-8278(24)02588-1","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"81 6","pages":"Pages e251-e260"},"PeriodicalIF":26.8,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}